Platelet activation has been associated with bad events like heart attack and stroke. There are a variety of platelet activators that regulate how active a platelet is. We are interested in Protease-activated receptors (PAR)-1. We are currently studying PAR-1 activation in persons with severe peripheral artery disease. We seek, through this project, to understand PAR-1 activation in persons without peripheral artery disease. As many patients with peripheral artery disease have diabetes, we will also evaluate PAR-1 activation in persons with type 2 diabetes. In addition we will assess the impact of the glucagon-like peptide (GLP)-1 signaling pathway on platelet activation. Levels of platelet activation will be determined using platelet aggregation experiments and assessment of platelet-monocyte aggregates in peripheral blood.

Inclusion Criteria:

• Healthy men and women ≥60 years of age OR
• Type 2 diabetic men and women ≥60 years of age

Exclusion Criteria:

• Active cancer
• Prior myocardial infarction, prior stroke, diagnosed peripheral artery disease
• Severe liver (cirrhosis, cancer, or end-stage liver disease), kidney disease (eGFR <30 cc/min).
• Pregnancy or lactation
• Active vasculitis
• Anticipated lifespan < 2 years
• Current use of a DOAC

Type 2 diabetic and healthy subjects

IPD that underlie results in a publication, after deidentification (text, tables, figures, and appendices).

Beginning 9 months and ending 36 months following article publication.

Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. (Link to be provided).